Innovative Practice in Breast Health最新文献

{"title":"Inference-based machine learning models to classify breast cancer subtypes","authors":"K.T. Shreya Parthasarathi ,&nbsp;Jyoti Sharma","doi":"10.1016/j.ibreh.2026.100051","DOIUrl":"10.1016/j.ibreh.2026.100051","url":null,"abstract":"<div><div>Breast cancer, a multifaceted disease, is classified into various subtypes. These subtypes are currently identified through immunohistochemistry or gene expression profiling, that in turn assist in determining appropriate treatment strategies. With the present therapeutics, breast cancer patients often undergo simultaneous side-effects during and after intense therapy, necessitating new biomarker-based targets. Ion channels regulate crucial cellular functions and can influence chemo-resistance and tumor growth. As significant drug targets, they offer promising therapeutic opportunities. Most recently, our group identified subtype alterations in ion channels and their regulatory elements in breast cancer, highlighting their potentiality for targeted treatment. Here, models based on support vector classifiers were developed, incorporating transcriptomic, methylomic, and genomic data. Using results from our previous analysis as features, these integrated models classified samples into molecular subtypes. The transcriptomic model could classify samples with a sensitivity of 0.63, specificity of 0.92 and area under the curve (AUC) of 0.77. The integrated methylomic-transcriptomic model could classify the same samples with a sensitivity of 0.71, specificity of 0.93 and AUC of 0.82 whereas the integrated genomic-methylomic-transcriptomic model resulted in a sensitivity of 0.63, specificity of 0.92 and AUC of 0.77. Utilising SHapley Additive exPlanations score calculations for features, the study further reports the ion channels in an order of importance taken into consideration by each model to classify each of the subtypes. Most likely, the study outlines a strategy for classifying breast cancer subtypes, emphasizing the potential role of ion channels in this classification, based on their observed alterations.</div></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"8 ","pages":"Article 100051"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147862536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A TCM-based continuing nursing care plan for chemotherapy-induced cancer-related fatigue in breast cancer patients: A best practices implementation","authors":"Juanya Chen,&nbsp;Meifen Dai,&nbsp;Yuzhen Liang,&nbsp;Jing Yang,&nbsp;Xiaoyun Li,&nbsp;Lihua Shan","doi":"10.1016/j.ibreh.2026.100052","DOIUrl":"10.1016/j.ibreh.2026.100052","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To implement an evidence-based transitional care program for breast cancer chemotherapy patients with cancer-related fatigue, developed based on traditional Chinese medicine principles, and to evaluate its clinical effectiveness, thereby providing high-quality nursing care guided by evidence-based practice for this patient population.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Breast cancer is one of the most prevalent malignant tumors among women globally,and chemotherapy remains one of its primary treatment modalities. Cancer-related fatigue (CRF) is the most frequent and distressing adverse effect associated with chemotherapy,affecting up to 96.97% of breast cancer patients undergoing this treatment. The implementation of a CRF nursing plan grounded in traditional Chinese medicine principles holds substantial significance for broadening the clinical management strategies for CRF in breast cancer patients receiving chemotherapy,thereby enhancing both the quality of nursing care and the overall quality of life for these patients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Breast cancer patients undergoing chemotherapy in the breast surgery department of a tertiary hospital were selected as participants, and an existing transitional care program for cancer-related fatigue based on traditional Chinese medicine principles was applied in clinical practice. Following the evidence-based nursing implementation process, 15 review indicators were established. Data were collected through methods such as medical record review, on-site inspections, and interviews. A total of 20 patients were included in the baseline group, the first intervention group, and the second intervention group, respectively, to track and observe the intervention effects. The chi-square test was used to compare differences in the incidence of cancer-related fatigue among patients at different time points.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Following the implementation of the TCM concept-based continuity nursing program, the compliance rates in the first and second rounds of the intervention group showed significant improvement compared to the baseline group across multiple aspects, including fatigue screening (χ²=43.636, &lt;em&gt;P&lt;/em&gt;&lt;0.001), symptom assessment (χ²=60.00, &lt;em&gt;P&lt;/em&gt;&lt;0.001), health education (χ²=47.442, &lt;em&gt;P&lt;/em&gt;&lt;0.001), and personalized fatigue management (χ²=33.600, &lt;em&gt;P&lt;/em&gt;&lt;0.001). Through two rounds of evidence-based practice, the incidence of moderate to severe cancer-related fatigue decreased from 80% in the baseline group to 30% in the second-round intervention group (χ²=11.297, &lt;em&gt;P&lt;/em&gt;&lt;0.005), indicating a significant improvement in the overall fatigue status of patients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;The application of a Traditional Chinese Medicine (TCM)-based transitional care program for cancer-related fatigue in breast cancer patients undergoing chemotherapy into evidence-based practice can significantly","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"8 ","pages":"Article 100052"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147807983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adaptive density-informed AI framework for improving breast cancer detection using mammography and thermal imaging","authors":"Siva Teja Kakileti ,&nbsp;Bharath Govindaraju ,&nbsp;Sudhakar Sampangi ,&nbsp;Geetha Manjunath","doi":"10.1016/j.ibreh.2026.100053","DOIUrl":"10.1016/j.ibreh.2026.100053","url":null,"abstract":"<div><h3>Background</h3><div>Mammographic screening performance declines in women with dense breasts, leading to diagnostic inequities and delayed cancer detection. Thermal imaging captures complementary functional cues such as vascular and metabolic activity that remain detectable irrespective of density with the help of Artificial Intelligence (AI). This study presents an adaptive Density-Informed Multimodal AI (DIMA) Framework that integrates mammography and thermal imaging to improve breast cancer detection performance across breast density categories.</div></div><div><h3>Methods</h3><div>The framework integrates two complementary AI pipelines: a multi-view deep learning model trained on 19,883 mammograms for morphological feature analysis, and a radiomics-based Thermalytix system trained on over 100,000 thermal images to capture vascular and thermal asymmetries. Breast density, categorized by ACR grades, functions as a conditional variable that dynamically determines which model’s prediction is used. The mammography AI is applied for fatty breasts (ACR A and B), whereas the Thermalytix AI is prioritized for dense breasts (ACR C and D). This density-conditioned decision logic enables optimal modality utilization while maintaining interpretability. To assess real-world applicability, the framework was evaluated on 324 women who underwent both mammography and thermal imaging.</div></div><div><h3>Results</h3><div>The DIMA framework achieved a sensitivity of 94.6% (95% CI: 88.6% –100%) and specificity of 79.9% (95% CI: 75.1%–84.7%), outperforming standalone mammography AI (sensitivity 81.8%, specificity 86.3%) and Thermalytix AI (sensitivity 92.7%, specificity 75.5%). Importantly, the sensitivity of Mammography dropped significantly in dense breasts (67.9%) versus fatty breasts (96.3%), whereas Thermalytix AI maintained high and consistent sensitivity in both (92.6% and 92.9%, respectively).</div></div><div><h3>Conclusions</h3><div>This retrospective cross-sectional diagnostic accuracy evaluation demonstrates the potential of a DIMA routing strategy to improve breast cancer detection across breast density categories. Population-based screening studies are required to assess its generalizability, equity, and role within large-scale screening programs.</div></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"8 ","pages":"Article 100053"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147862537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salvage of a laparoscopically harvested omental flap by conversion to a free flap with microanastomosis to thoracodorsals for immediate breast reconstruction","authors":"Annie Wu,&nbsp;Sarah Appleton,&nbsp;Muriel Brackstone,&nbsp;Ahmad Elnahas,&nbsp;Allison Maciver","doi":"10.1016/j.ibreh.2026.100054","DOIUrl":"10.1016/j.ibreh.2026.100054","url":null,"abstract":"<div><div>We describe intraoperative salvage of a planned pedicled omental flap for immediate breast reconstruction by conversion to a free omental flap with microanastomosis to the serratus branch of the thoracodorsal recipient pedicle. To our knowledge, this is among the earliest North American reports for the feasibility of the thoracodorsal system in this salvage context and provides technical detail for managing pedicle compromise during omental-based reconstruction.</div></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"8 ","pages":"Article 100054"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148769940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advancements in machine learning and deep learning for early detection of breast cancer: A comprehensive review","authors":"Tangin Amir Smrity,&nbsp;MD Zahin Muntaqim,&nbsp;Hasan Muhammad Kafi","doi":"10.1016/j.ibreh.2026.100050","DOIUrl":"10.1016/j.ibreh.2026.100050","url":null,"abstract":"<div><div>Breast cancer remains one of the most prevalent and life-threatening diseases affecting women globally. Early and accurate detection is crucial for effective treatment and improved survival rates. In recent years, Machine Learning (ML) and Deep Learning (DL) techniques have shown significant promise in enhancing the accuracy, speed, and reliability of breast cancer diagnosis and classification. This review presents a comprehensive analysis and quality assessment of research studies published between 2020 and 2025, evaluating dataset representativeness, reference standards, validation methodology, and risk of bias using adapted QUADAS-AI Framework, focusing on ML and DL-based approaches applied to breast cancer detection and classi-fication. We categorize the reviewed literature based on the type of input data (e.g., mammograms, histopathological images, ultrasound, and clinical data), learning models (such as Support Vector Machines, Random Forests, Convolutional Neural Networks, and Transformers), and performance metrics used. Additionally, we highlight key trends, challenges, and innovations, including the rise of hybrid models, transfer learning, and explainable AI in medical diagnostics. This review aims to provide researchers and clinicians with a structured understanding of the recent advancements and future directions in AI-driven breast cancer diagnostics.</div></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"8 ","pages":"Article 100050"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147862117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound-guided marker clip placement and biopsy in level II axillary lymph nodes","authors":"D Lewis ,&nbsp;M Russell ,&nbsp;CMG Schammel ,&nbsp;JA Epling","doi":"10.1016/j.ibreh.2025.100044","DOIUrl":"10.1016/j.ibreh.2025.100044","url":null,"abstract":"<div><div>Axillary lymph node staging is critical in breast cancer management, but localization of Level II nodes poses technical challenges due to their deep and variable anatomy. We present a case of a 39-year-old woman with invasive ductal carcinoma and isolated Level II axillary nodal metastases. Ultrasound-guided core biopsy with marker clip placement was performed on a lateral Level II node, while a medial Level II node was marked without biopsy. Preoperative wire localization was facilitated by these clips, enabling targeted surgical excision of the nodes. Surgical pathology confirmed residual metastatic involvement, and the patient proceeded with adjuvant therapy. This case highlights the utility of ultrasound-guided biopsy and marker clip placement for accurate localization and management of challenging Level II axillary nodes. Emerging localization technologies such as magnetic seed and radiofrequency identification (RFID) tags offer promising, radiation-free alternatives to wire-guided localization and may improve operative planning and patient outcomes. Further research is needed to standardize these techniques and validate long-term oncologic efficacy.</div></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"7 ","pages":"Article 100044"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144771323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bosutinib: Transforming the therapeutic landscape for HER2-positive and triple-negative breast cancer","authors":"Rishabh Agade,&nbsp;Ujban Hussain,&nbsp;Aditya R. Wadalkar,&nbsp;Abhijeet A. Chalkhor,&nbsp;Prashant K. Puranik,&nbsp;Veena Belgamwar","doi":"10.1016/j.ibreh.2025.100042","DOIUrl":"10.1016/j.ibreh.2025.100042","url":null,"abstract":"<div><div>Breast cancer remains one of the most prevalent and challenging malignancies, especially in aggressive subtypes such as HER2-positive and triple-negative breast cancer (TNBC). These subtypes are characterized by rapid proliferation, high metastatic potential, and resistance to conventional therapies, leading to poor prognosis. Bosutinib, a second-generation tyrosine kinase inhibitor, has emerged as a promising therapeutic candidate due to its dual inhibition of SRC family and Abl kinases, which are pivotal in cancer cell proliferation, survival, and metastasis. Preclinical and clinical studies indicate that bosutinib effectively suppresses tumor growth, induces apoptosis, and reduces metastatic potential. Moreover, its combination with existing therapies, such as trastuzumab or immune checkpoint inhibitors, enhances therapeutic efficacy, particularly in resistant cases. Innovative strategies, including nanoparticle-based delivery systems, further improve bosutinib’s bioavailability and targeted action, minimizing systemic toxicity. However, challenges such as resistance development and toxicity management require ongoing investigation. This review underscores bosutinib’s potential in addressing therapeutic resistance and highlights its role in precision medicine, advancing breast cancer treatment.</div></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"7 ","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic excision results in benign and borderline breast lesions by the breast lesion excision system (BLES)","authors":"Mirsad Yalcinkaya ,&nbsp;Mehmet Ali Nazlı ,&nbsp;Canan Kelten Talu ,&nbsp;Gultekin Ozan Kucuk ,&nbsp;Ozgur Kılıckesmez","doi":"10.1016/j.ibreh.2025.100043","DOIUrl":"10.1016/j.ibreh.2025.100043","url":null,"abstract":"<div><h3>Background</h3><div>Breast lesion excision system (BLES) is an alternative biopsy method that allows large specimens to be received from the tissue.</div></div><div><h3>Objectives</h3><div>This study aims to evaluate the therapeutic results of the biopsies performed breast lesions using the BLES.</div></div><div><h3>Methods</h3><div>The study included 23 patients who underwent biopsy with the BLES between January 2014 and December 2016. All of the relevant procedures were performed under local anesthesia. After the procedure, the excision site was closely observed using ultrasonography and analyzed for macroscopic residual lesions. All specimens were evaluated using the diagnostic or therapeutic accuracy or safety of BLES.</div></div><div><h3>Results</h3><div>The mean lesion size was 11.3 ± 4.4 mm. The size was ≤10 mm in 11 patients, and between 10 mm and 20 mm in 12 patients. Pathologic evaluation could not be performed in 1 patient due to an empty basket. According to the first BLES procedure, in the patient group with a target lesion size ≤10 mm, complete removal was achieved in 9 patients (90.0 %) and incomplete removal in 1 patient (10.0 %). In the patient group with a target lesion size between 10 mm and 20 mm, complete removal was achieved in 5 patients (42 %) and incomplete removal in 7 patients (58 %) (<em>p</em> = 0.019). No complications such as bleeding, hematoma, or infection were detected in our study.</div></div><div><h3>Conclusion</h3><div>BLES is a minimally invasive, safe and effective alternative to surgical excision, especially in suitable sizes, as it does not require general anesthesia and can be done as an outpatient procedure.</div></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"7 ","pages":"Article 100043"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genome medicine and breast cancer in Africa","authors":"Abdullahi Tunde Aborode ,&nbsp;Soyemi Toluwalashe ,&nbsp;Ibrahim O. Adelakun ,&nbsp;Segun Olapade ,&nbsp;Segun E. Ogungbemi ,&nbsp;Boluwatife T. Dosunmu ,&nbsp;Isreal Ayobami Onifade ,&nbsp;Ridwan Olamilekan Adesola ,&nbsp;Adetolase Azizat Bakre ,&nbsp;Godfred Yawson Scott","doi":"10.1016/j.ibreh.2025.100040","DOIUrl":"10.1016/j.ibreh.2025.100040","url":null,"abstract":"","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"7 ","pages":"Article 100040"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144518509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the potential of CRISPR in triple-negative breast cancer treatment","authors":"Lopamudra Chakravarty ,&nbsp;Sk Imtiaz Ahmad ,&nbsp;Afsona Khatun ,&nbsp;Sahabaj Ali Khan","doi":"10.1016/j.ibreh.2024.100028","DOIUrl":"10.1016/j.ibreh.2024.100028","url":null,"abstract":"<div><div>The CRISPR/Cas9 gene editing system, derived from prokaryotic adaptive defense mechanisms, has revolutionized various fields by enabling precise gene editing. Its impact has been particularly significant in cancer research, facilitating improved disease modeling, identification of new cancer-related genes, and more accurate diagnosis, especially for challenging subtypes like triple-negative breast cancer (TNBC). TNBC's resistance to targeted therapies due to the absence of hormone receptors underscores the importance of CRISPR technology. Utilizing guide RNA to direct Cas9 enzyme to specific genomic loci, the CRISPR system induces double-strand breaks, which are repaired by endogenous DNA repair mechanisms, enabling gene insertions, deletions, or modifications. The CRISPR process involves three key steps: guide RNA design and complex formation with Cas9, DNA cleavage at the target site, and cellular repair through non-homologous end joining or homology-directed repair pathways. With its versatility and precision, CRISPR/Cas9 emerges as a potent tool driving innovative cancer research and therapeutic development.</div></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"7 ","pages":"Article 100028"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}